About The Study: In this cohort study of individuals with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use was associated with a modestly increased risk of incident diabetic retinopathy (DR); however, fewer patients experienced sight-threatening DR complications, including blindness, even among those with preexisting DR. These findings suggest that all patients with T2D treated with GLP-1 RAs, regardless of preexisting DR, should be regularly screened and monitored for potential complications of T2D.
Corresponding Author: To contact the corresponding author, Sarju Ganatra, MD, email sarju.ganatra@lahey.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.26321)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.26321?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081125
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open